A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections

Table 1 Demographic and baseline characteristics of the mITT population ^‡

	Tigecycline (n = 268)	Comparator (n = 263)
Age, years, mean (SD)	51.1 (16.11)	51.54 (16.90)
Males (%)	60.8	64.3
Ethnic origin (%)
White	52.6	55.5
Asian	22.4	22.1
Black	16.4	15.2
Hispanic	5.6	4.9
Other	3.0	2.3
Weight, mean (SD)	87.8 (30.6)	90.4 (34.8)
Creatinine clearance, mL/min, mean (SD)	114.23 (60.73)	112.88 (59.94)
Comorbid conditions (%)
Diabetes mellitus	31.7	32.7
Peripheral vascular disease	14.2	11.0
IV drug use	4.5	4.6
Prior antibiotic failure (%)	20.5	22.4
Clinical diagnosis, n (%)*
Deep soft tissue infection^†	186 (69.4)	176 (66.9)
Major abscesses	47 (17.5)	60 (22.8)
Infected ulcers	31 (11.6)	26 (9.9)

*Includes 3 burns and 1 “other” diagnosis in tigecycline subjects and 1 burn in comparator subjects. ^†Includes cellulitis (168 and 166 patients in the tigecycline and comparator groups, respectively), wound infections (8 and 6 patients, respectively), bites (8 and 4 patients, respectively), and IV catheter infections (2 and 0 patients, respectively). ^‡No statistically significant differences between groups. mITT, modified intent-to-treat; SD, standard deviation.

ISSN: 1471-2334